A case-donor was defined as a donor of blood to the ARCBS during the study period who had repeatedly reactive ELISAs for HTLV-1 on a single donated specimen that were unconfirmed for anti-HTLV-1 on supplemental assays including Western blot (WB) assay.
Review of 397 blood-donation records randomly sampled from records of the 12,221 donors of blood to the ARCBS during the study period indicated that 15 (3.8% [95% CI=2.0%-5.7%]) blood donors reported antecedent receipt of influenza vaccination during the 12 months before blood donation.
To examine the potential for HIV-2 infection in blood supplies, the ARCBS and the NYBC tested stored frozen serum (collected from January 1987 to December 1989) that had previously tested repeatedly reactive by the HIV-1 enzyme immunoassay (EIA) (serum from persons with HIV-2 infection often cross-reacts with HIV-1 EIA [1,2]).
The ARCBS and the NYBC screened donors with the licensed Abbott (*) (North Chicago, Illinois) and Dupont/Biotech (Wilmington, Delaware) whole-virus lysate HIV-1 EIAs, respectively.
Twenty-six blinded HIV-2-positive control specimens (1) 141 HIV-1 EIA-negative control specimens, and 2415 specimens from ARCBS and NYBC that tested repeatedly reactive by the HIV-2 EIA were sent to CDC for further testing with investigational HIV-1 and HIV-2 EIA peptide assays (Genetic Systems, Seattle, Washington).